PDA

View Full Version : Amgen, Takeda and Millennium update on phase 3 trial of Motesanib in non-small cell l


News
11-19-2008, 09:20 PM
Amgen and Millennium: The Takeda Oncology Company, a subsidiary of Takeda Pharmaceutical Company Limited , today announced that enrollment in the Phase 3 MONET1 trial evaluating motesanib (AMG 706) in combination with paclitaxel and carboplatin for the first-line treatment of advanced non-small cell lung cancer (NSCLC) has been temporarily suspended following a planned safety data review of 600 patients by the study's independent Data Monitoring Committee (DMC). Motesanib is part of a broad co-development program between Amgen and Takeda.

More... (http://www.news-medical.net/?id=43165)